ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · Real-Time Price · USD
4.380
-0.020 (-0.45%)
Dec 20, 2024, 4:00 PM EST - Market closed
ReShape Lifesciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 8.18 | 8.68 | 11.24 | 13.6 | 11.3 | 15.09 | Upgrade
|
| Revenue Growth (YoY) | -16.55% | -22.79% | -17.35% | 20.36% | -25.12% | 2385.83% | Upgrade
|
| Cost of Revenue | 2.6 | 3.13 | 4.44 | 5.25 | 5.04 | 5.78 | Upgrade
|
| Gross Profit | 5.58 | 5.55 | 6.8 | 8.35 | 6.26 | 9.31 | Upgrade
|
| Selling, General & Admin | 11.48 | 17.87 | 31.34 | 30.94 | 15.22 | 22.07 | Upgrade
|
| Research & Development | 2.02 | 2.32 | 2.54 | 2.37 | 3.5 | 3.12 | Upgrade
|
| Operating Expenses | 13.5 | 20.19 | 33.88 | 33.3 | 18.72 | 25.19 | Upgrade
|
| Operating Income | -7.92 | -14.64 | -27.08 | -24.96 | -12.46 | -15.89 | Upgrade
|
| Interest Expense | - | - | -0.11 | -0.83 | -2.05 | -0.45 | Upgrade
|
| Interest & Investment Income | 0.03 | 0.03 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.08 | 0.02 | -0.14 | 0.17 | 0.41 | 0.25 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.38 | 4 | 0.01 | -2.81 | - | -50.36 | Upgrade
|
| EBT Excluding Unusual Items | -7.43 | -10.59 | -27.32 | -28.43 | -14.1 | -66.46 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -2.28 | - | - | Upgrade
|
| Impairment of Goodwill | - | - | - | -23.5 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.03 | -0.53 | - | - | -0.49 | Upgrade
|
| Asset Writedown | - | -0.78 | -18.74 | -7.15 | - | -6.59 | Upgrade
|
| Legal Settlements | - | - | - | - | - | -1.5 | Upgrade
|
| Other Unusual Items | 0.43 | - | - | -2.06 | -7.72 | -0.07 | Upgrade
|
| Pretax Income | -7 | -11.34 | -46.59 | -63.42 | -21.81 | -75.1 | Upgrade
|
| Income Tax Expense | 0.07 | 0.05 | -0.38 | -0.27 | -0.18 | -0.89 | Upgrade
|
| Earnings From Continuing Operations | -7.07 | -11.39 | -46.21 | -63.15 | -21.63 | -74.21 | Upgrade
|
| Net Income | -7.07 | -11.39 | -46.21 | -63.15 | -21.63 | -74.21 | Upgrade
|
| Net Income to Common | -7.07 | -11.39 | -46.21 | -63.15 | -21.63 | -74.21 | Upgrade
|
| Shares Outstanding (Basic) | 0 | 0 | - | - | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 0 | 0 | - | - | - | - | Upgrade
|
| EPS (Basic) | -17.51 | -110.88 | - | - | - | - | Upgrade
|
| EPS (Diluted) | -17.51 | -110.88 | - | - | - | - | Upgrade
|
| Free Cash Flow | -6.2 | -17 | -22.03 | -15.73 | -8.94 | -14.21 | Upgrade
|
| Free Cash Flow Per Share | -15.36 | -165.56 | - | - | - | - | Upgrade
|
| Gross Margin | 68.19% | 63.93% | 60.52% | 61.38% | 55.42% | 61.67% | Upgrade
|
| Operating Margin | -96.80% | -168.69% | -240.91% | -183.50% | -110.25% | -105.29% | Upgrade
|
| Profit Margin | -86.36% | -131.22% | -411.16% | -464.31% | -191.43% | -491.80% | Upgrade
|
| Free Cash Flow Margin | -75.73% | -195.93% | -196.02% | -115.64% | -79.12% | -94.20% | Upgrade
|
| EBITDA | -7.9 | -14.49 | -24.93 | -22.99 | -10.79 | -14.18 | Upgrade
|
| EBITDA Margin | -96.50% | -166.92% | -221.75% | -169.01% | -95.50% | -93.98% | Upgrade
|
| D&A For EBITDA | 0.02 | 0.15 | 2.15 | 1.97 | 1.67 | 1.71 | Upgrade
|
| EBIT | -7.92 | -14.64 | -27.08 | -24.96 | -12.46 | -15.89 | Upgrade
|
| EBIT Margin | -96.80% | -168.69% | -240.91% | -183.50% | -110.25% | -105.29% | Upgrade
|
| Advertising Expenses | - | 2.2 | 6.8 | 3 | 0.5 | 0.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.